207 related articles for article (PubMed ID: 7532147)
1. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
Bonkhoff H; Stein U; Remberger K
Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.
Bonkhoff H; Stein U; Remberger K
Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):291-4. PubMed ID: 7694424
[TBL] [Abstract][Full Text] [Related]
3. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate.
Bonkhoff H; Wernert N; Dhom G; Remberger K
Prostate; 1991; 19(2):91-8. PubMed ID: 1717965
[TBL] [Abstract][Full Text] [Related]
4. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
Bonkhoff H
Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation.
Bonkhoff H; Stein U; Welter C; Remberger K
Hum Pathol; 1995 Aug; 26(8):824-8. PubMed ID: 7635445
[TBL] [Abstract][Full Text] [Related]
7. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of chromogranins A and B and secretogranin II in normal, hyperplastic and neoplastic prostate.
Schmid KW; Helpap B; Tötsch M; Kirchmair R; Dockhorn-Dworniczak B; Böcker W; Fischer-Colbrie R
Histopathology; 1994 Mar; 24(3):233-9. PubMed ID: 7515371
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
[TBL] [Abstract][Full Text] [Related]
10. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
11. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
Abrahamsson PA; Falkmer S; Fält K; Grimelius L
Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
[TBL] [Abstract][Full Text] [Related]
12. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers.
Bonkhoff H; Stein U; Remberger K
Hum Pathol; 1994 Jan; 25(1):42-6. PubMed ID: 7508883
[TBL] [Abstract][Full Text] [Related]
13. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
17. Paneth cell-like change of the prostate gland. A histological, immunohistochemical, and electron microscopic study.
Weaver MG; Abdul-Karim FW; Srigley J; Bostwick DG; Ro JY; Ayala AG
Am J Surg Pathol; 1992 Jan; 16(1):62-8. PubMed ID: 1370193
[TBL] [Abstract][Full Text] [Related]
18. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
19. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]